MedTrace Logo

Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension

NCT02042066 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-01-22

No results posted yet for this study

Summary

Low intensity shockwaves have been proven in animal and human studies to increase tissue perfusion, promote angiogenesis and tissue regeneration and improve neural function.

The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with resistant hypertension.

Conditions

  • Hypertension, Resistant to Conventional Therapy

Interventions

DEVICE

Omnispec model Vascuspec

Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy

Sponsors & Collaborators

  • Hadassah Medical Organization

    collaborator OTHER

  • Medispec

    lead INDUSTRY

Principal Investigators

  • Ayelet Shauer, MD · Hadassah Medical Organization

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-01-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02042066 on ClinicalTrials.gov